5/4/2023

Ioversol Injection

Products Affected - Description

- Optiray 300 solution for injection, Guerbet, 100 mL bottle, 12 count, NDC 00019-1332-11 - discontinued
- Optiray 300 solution for injection, Guerbet, 100 mL prefilled syringe, 20 count, NDC 00019-1332-90 - discontinued
- Optiray 300 solution for injection, Guerbet, 100 mL RFID technology prefilled syringe, NDC 00019-1332-00 - discontinued
- Optiray 300 solution for injection, Guerbet, 200 mL bottle, 12 count, NDC 00019-1332-21 - discontinued
- Optiray 300 solution for injection, Guerbet, 50 mL Hand Held prefilled syringe, 20 count, NDC 00019-1332-78
- Optiray 300 solution for injection, Guerbet, 50 mL vial, 25 count, NDC 00019-1332-06 - discontinued
- Optiray 300 solution for injection, Guerbet, 500 mL pharmacy bulk pack, multi-dose bottle, 6 count, NDC 00019-1332-61 - discontinued
- Optiray 320 solution for injection, Guerbet, 100 mL bottle, 12 count, NDC 00019-1323-11
- Optiray 320 solution for injection, Guerbet, 100 mL prefilled syringe, 20 count, NDC 00019-1323-90
- Optiray 320 solution for injection, Guerbet, 100 mL RFID technology prefilled syringe, NDC 00019-1323-00 - discontinued
- Optiray 320 solution for injection, Guerbet, 125 mL prefilled syringe, 20 count, NDC 00019-1323-87
- Optiray 320 solution for injection, Guerbet, 125 mL RFID technology prefilled syringe, NDC 00019-1323-27 - discontinued
- Optiray 320 solution for injection, Guerbet, 150 mL bottle, 12 count, NDC 00019-1323-16
- Optiray 320 solution for injection, Guerbet, 20 mL vial, 25 count, NDC 00019-1323-02 - discontinued
- Optiray 320 solution for injection, Guerbet, 200 mL bottle, 12 count, NDC 00019-1323-21
- Optiray 320 solution for injection, Guerbet, 30 mL vial, 25 count, NDC 00019-1323-04 - discontinued
- Optiray 320 solution for injection, Guerbet, 50 mL Hand Held prefilled syringe, 20 count, NDC 00019-1323-78 - discontinued
- Optiray 320 solution for injection, Guerbet, 50 mL prefilled syringe, 20 count, NDC 00019-1323-52
- Optiray 320 solution for injection, Guerbet, 50 mL vial, 25 count, NDC 00019-1323-06
- Optiray 320 solution for injection, Guerbet, 500 mL pharmacy bulk pack, multi-dose bottle, 6 count, NDC 00019-1323-61 - discontinued
- Optiray 320 solution for injection, Guerbet, 500 mL Imaging Bulk Package, bottle, 6 count, NDC 00019-1323-65
- Optiray 320 solution for injection, Guerbet, 75 mL prefilled syringe, 20 count, NDC 00019-1323-95
- Optiray 320 solution for injection, Guerbet, 75 mL RFID technology prefilled syringe, NDC 00019-1323-85 - discontinued
- Optiray 350 solution for injection, Guerbet, 100 mL bottle, 12 count, NDC 00019-1333-11
- Optiray 350 solution for injection, Guerbet, 100 mL prefilled syringe, 20 count, NDC 00019-1333-90
- Optiray 350 solution for injection, Guerbet, 100 mL RFID technology prefilled syringe, NDC 00019-1333-00 - discontinued
- Optiray 350 solution for injection, Guerbet, 125 mL prefilled syringe, 20 count, NDC 00019-1333-87
- Optiray 350 solution for injection, Guerbet, 125 mL RFID technology prefilled syringe, NDC 00019-1333-27 - discontinued
- Optiray 350 solution for injection, Guerbet, 150 mL bottle, 12 count, NDC 00019-1333-16
- Optiray 350 solution for injection, Guerbet, 200 mL bottle, 12 count, NDC 00019-1333-21
- Optiray 350 solution for injection, Guerbet, 50 mL Hand Held prefilled syringe, 20 count, NDC 00019-1333-78 - discontinued
- Optiray 350 solution for injection, Guerbet, 50 mL prefilled syringe, 20 count, NDC 00019-1333-52 - discontinued
- Optiray 350 solution for injection, Guerbet, 50 mL RFID technology prefilled syringe, NDC 00019-1333-55 - discontinued
- Optiray 350 solution for injection, Guerbet, 50 mL vial, 25 count, NDC 00019-1333-06
- Optiray 350 solution for injection, Guerbet, 500 mL pharmacy bulk pack, multi-dose bottle, 6 count, NDC 00019-1333-61 - discontinued
- Optiray 350 solution for injection, Guerbet, 75 mL prefilled syringe, 20 count, NDC 00019-1333-95

Reason for the Shortage

- Guerbet states Optiray is on back order due to a shortage of raw material. All Optiray-300 products were discontinued in early 2023.

Available Products

- There are no presentations available.

Estimated Resupply Dates

- Guerbet has Optiray 320 in 50 mL, 75 mL, and 100 mL power syringes on back order and the company estimates a release date in July 2023. Optiray 320 in 50 mL vials, 100 mL bottles, 150 mL bottles are on allocation. Optiray 320 in 200 mL bottles and 500 mL imaging bulk packages are on back order with an estimated a release date of early-May 2023. Optiray 320 in 125 mL power syringes are on back order and the company estimates a release date in late-June 2023.
- Guerbet has Optiray 350 in 200 mL bottles are on back order and the company cannot estimate a release date. Optiray 350 in 100 mL power injector syringe and 125 mL power injector syringe are on back order with an estimated release date in late-June 2023 for the 100 mL power injector syringes and mid-June 2023 for the 125 mL power injector syringes. Optiray 350 in 150 mL glass bottles are on back order and the company estimates a release date in early-May 2023. Optiray 350 in 50 mL glass bottles, 100 mL glass bottles, and 75 mL power injector syringes are on allocation.

Alternative Agents & Management

- More information can be found at Considerations for Imaging Contrast Shortage Management and Conservation
- The American College of Radiology (ACR) has issued a statement addressing the shortage of iodinated contrast media. https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Contrast-Media-Shortage

Updated

Updated May 4, 2023 by Elyse MacDonald, PharmD, MS, BCPS. Created May 20, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.